Nimorazole

PreclinicalSmall molecule

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Nimorazole is one of 52 small molecule programs targeting Squamous Cell Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Squamous Cell CarcinomaActive, not recruiting

Squamous Cell CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

64 competitors in Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

59 2

Taxotere

AAvyxa

Approved

30 3

Keytruda

Merck & Co.

Phase 3

19 4

Erbitux

IImclone

Phase 3

45 5

Gemzar

Bayer Aspirin

Opdivo

14 8

Taxol

Teva

Phase 3

12 9

Tecentriq

Roche

Phase 3

7 10

Paraplatin

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

N/AActive, not recruiting

Squamous Cell Carcinoma

NCT04124198

Clinical

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma2 trials

NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)

Completed·TThe Christie NHS Foundation Trust·Phase 3·NCT01950689·338 enrolled

DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification With Nimorazole During Radiotherapy/Chemoradiotherapy of Squamous Cell Carcinoma of the Head and Neck.

Completed·DDanish Head and Neck Cancer Group·Phase 3·NCT02661152·1,252 enrolled

Squamous Cell Carcinoma1 trial

Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma

Active, not recruiting·CChristian von Buchwald·N/A·NCT04124198·138 enrolled

HNSCC1 trial

AF CRT +/- Nimorazole in HNSCC

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT01880359·640 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Nimorazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nimorazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nimorazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — European Organisation for Research and Treatment of Cancer - EORTC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEuropean Organisation for Research and Treatment of Cancer - EORTC

Nimorazole

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma2 trials

Squamous Cell Carcinoma1 trial

HNSCC1 trial

References

Drug Info

Quick Facts

Related News